The Relationgship Between Adherence And Clinical Of Imatinib Therapy In Gastrointestinal Stromal Tumor

Objective:To investigate the relationship between adherence andclinical of imatinib therapy in gastrointestinal stromal tumor.Method:To Analyze the clinical data of151cases of GIST whichhave registered as members of GIPAP (Glivec International PatientAssistance Program).All patients was treated with Imatinib Mesylate. Anduse the self-designed medication compliance questionnaire to determine theadherence rates in patients.Compare the clinical outcomes of the patientswith difference compliance.Results:The group of151cases of patients.120patients hadandergone surgery prior to initiation imatinib treatment,high-risk45casesand medium risk75cases.Preoperative treatment of6cases. Unresectablerecurrence, metastasis in25cases.The overall outcomes of imatinibtreatment is good.But the evidence showing the effects of nonadherenceon patients outcomes as well as data indicating that adherence to imatinib issuboptimal.Conclusion: Imatinib mesylate has a positive curative effect for GISTtreatment, including the preoperative therapy,postopration adjuvant therapy, unresectable and recurrent treatment of gastrointestinal stromaltumor.Adherence to imatinib therapy in gastrointestinal stromal tumorsplays a important role. It can directly affect the curative effect.But there arestill many problems to be solved,such as the best course of treatment, thedrug of choice et al.